{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T09:51:47Z","timestamp":1776160307290,"version":"3.50.1"},"reference-count":154,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.neurol.2026.01.269","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T22:09:07Z","timestamp":1772489347000},"page":"231-247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognosis biomarkers in MOGAD: What can we learn from observational studies?"],"prefix":"10.1016","volume":"182","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6828-3877","authenticated-orcid":false,"given":"B.","family":"Lemarchant","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5323-911X","authenticated-orcid":false,"given":"P.","family":"Cleuziou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9271-8776","authenticated-orcid":false,"given":"S.","family":"Rogeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.-S.","family":"Deleplancque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Outteryck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4029-2012","authenticated-orcid":false,"given":"H.","family":"Z\u00e9phir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2026.01.269_bib0775","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1471-4159.1989.tb10930.x","article-title":"Differential ultrastructural localization of myelin basic protein, myelin\/oligodendroglial glycoprotein, and 2\u2032,3\u2032-cyclic nucleotide 3\u2032-phosphodiesterase in the CNS of adult rats","volume":"52","author":"Brunner","year":"1989","journal-title":"J Neurochem"},{"key":"10.1016\/j.neurol.2026.01.269_bib0780","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3389\/fimmu.2017.00529","article-title":"Myelin oligodendrocyte glycoprotein: deciphering a target in inflammatory demyelinating diseases","volume":"8","author":"Peschl","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurol.2026.01.269_bib0785","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1056\/NEJMoa022328","article-title":"Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event","volume":"349","author":"Berger","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2026.01.269_bib0790","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/ana.21916","article-title":"Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease","volume":"66","author":"Brilot","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2026.01.269_bib0795","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1212\/NXI.0000000000000089","article-title":"MOG cell-based assay detects non-MS patients with inflammatory neurologic disease","volume":"2","author":"Waters","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.neurol.2026.01.269_bib0800","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.neurol.2026.01.269_bib0805","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2026.01.269_bib0810","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/brain\/awaa102","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study","volume":"143","author":"Takai","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2026.01.269_bib0815","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00401-020-02132-y","article-title":"The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody","volume":"139","author":"H\u00f6ftberger","year":"2020","journal-title":"Acta Neuropathol (Berl)"},{"key":"10.1016\/j.neurol.2026.01.269_bib0820","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1471-4159.1999.0720001.x","article-title":"The structure and function of myelin oligodendrocyte glycoprotein","volume":"72","author":"Johns","year":"1999","journal-title":"J Neurochem"},{"key":"10.1016\/j.neurol.2026.01.269_bib0825","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1007\/s00415-017-8635-4","article-title":"Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study","volume":"264","author":"Mariotto","year":"2017","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2026.01.269_bib0830","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1073\/pnas.1519608113","article-title":"Autoantibody-boosted T-cell reactivation in the target organ triggers manifestation of autoimmune CNS disease","volume":"113","author":"Flach","year":"2016","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.neurol.2026.01.269_bib0835","first-page":"443","article-title":"Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin\/oligodendrocyte glycoprotein","volume":"130","author":"Linington","year":"1988","journal-title":"Am J Pathol"},{"key":"10.1016\/j.neurol.2026.01.269_bib0840","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ana.25291","article-title":"Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein","volume":"84","author":"Spadaro","year":"2018","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2026.01.269_bib0845","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain J Neurol"},{"key":"10.1016\/j.neurol.2026.01.269_bib0850","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1136\/bjophthalmol-2017-311177","article-title":"Clinical features of demyelinating optic neuritis with seropositive myelin oligodendrocyte glycoprotein antibody in Chinese patients","volume":"102","author":"Zhao","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.neurol.2026.01.269_bib0855","first-page":"8","article-title":"Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome","volume":"195","author":"Chen","year":"2018","journal-title":"Ophthalmol"},{"key":"10.1016\/j.neurol.2026.01.269_bib0860","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00415-017-8651-4","article-title":"Clinical characteristics of myelin oligodendrocyte glycoprotein seropositive optic neuritis: a cohort study in Shanghai, China","volume":"265","author":"Zhao","year":"2018","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2026.01.269_bib0865","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2026.01.269_bib0870","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/jamaneurol.2018.4053","article-title":"Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody","volume":"76","author":"Dubey","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2026.01.269_bib0875","doi-asserted-by":"crossref","first-page":"e1351","DOI":"10.1212\/WNL.0000000000012599","article-title":"CNS demyelinating attacks requiring ventilatory support with myelin oligodendrocyte glycoprotein or aquaporin-4 antibodies","volume":"97","author":"Zhao-Fleming","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.01.269_bib0880","doi-asserted-by":"crossref","first-page":"e200020","DOI":"10.1212\/NXI.0000000000200020","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease presenting as intracranial hypertension: a case report","volume":"9","author":"Chaudhuri","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.neurol.2026.01.269_bib0885","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/jnnp-2020-325121","article-title":"Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS","volume":"92","author":"Banks","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2026.01.269_bib0890","doi-asserted-by":"crossref","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.01.269_bib0895","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1001\/jamaneurol.2020.3115","article-title":"Long-term outcomes in patients with myelin oligodendrocyte glycoprotein immunoglobulin G\u2013associated disorder","volume":"77","author":"Lopez-Chiriboga","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2026.01.269_bib0900","doi-asserted-by":"crossref","first-page":"e209624","DOI":"10.1212\/WNL.0000000000209624","article-title":"Early maintenance treatment initiation and relapse risk mitigation after a first event of MOGAD in Adults: the MOGADOR2 Study","volume":"103","author":"Deschamps","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.01.269_bib0905","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/jnnp-2022-330360","article-title":"Time to steroids impacts visual outcome of optic neuritis in MOGAD","volume":"94","author":"Rode","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2026.01.269_bib0910","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2026.01.269_bib0915","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/acn3.51750","article-title":"Low mortality rate in a large cohort of myelin oligodendrocyte glycoprotein antibody disease (MOGAD)","volume":"10","author":"Lotan","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurol.2026.01.269_bib0920","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ana.25909","article-title":"Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"89","author":"Cobo-Calvo","year":"2021","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2026.01.269_bib0925","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/brain\/awaa199","article-title":"Improved relapse recovery in paediatric compared to adult multiple sclerosis","volume":"143","author":"Chitnis","year":"2020","journal-title":"Brain J Neurol"},{"key":"10.1016\/j.neurol.2026.01.269_bib0930","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12974-021-02160-9","article-title":"Age-dependent favorable visual recovery despite significant retinal atrophy in pediatric MOGAD: how much retina do you really need to see well?","volume":"18","author":"Havla","year":"2021","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.neurol.2026.01.269_bib0935","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1474-4422(19)30488-0","article-title":"Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study","volume":"19","author":"Armangue","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2026.01.269_bib0940","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/dmcn.13649","article-title":"Leukodystrophy-like\u2019 phenotype in children with myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"60","author":"Hacohen","year":"2018","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.neurol.2026.01.269_bib0945","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/s12883-023-03294-4","article-title":"Two rare cases of myelin oligodendrocyte glycoprotein antibody-associated disorder in children with leukodystrophy-like imaging findings","volume":"23","author":"Wang","year":"2023","journal-title":"BMC Neurol"},{"key":"10.1016\/j.neurol.2026.01.269_bib0950","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1177\/19418744231192159","article-title":"Perplexing initial presentations of MOGAD in two children: intracranial hypertension and new-onset seizure","volume":"13","author":"Zhou","year":"2023","journal-title":"The Neurohospitalist"},{"key":"10.1016\/j.neurol.2026.01.269_bib0955","doi-asserted-by":"crossref","first-page":"e200150","DOI":"10.1212\/NXI.0000000000200150","article-title":"Dramatic response to anti-il-6 receptor therapy in children with life-threatening myelin oligodendrocyte glycoprotein-associated disease","volume":"10","author":"McLendon","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.neurol.2026.01.269_bib0960","doi-asserted-by":"crossref","first-page":"e200174","DOI":"10.1212\/NXI.0000000000200174","article-title":"Increased intracranial pressure in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"11","author":"Nguyen","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.neurol.2026.01.269_bib0965","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1136\/jnnp-2024-334613","article-title":"Fewer relapses and worse outcomes of patients with late-onset myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"96","author":"Fan","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2026.01.269_bib0970","doi-asserted-by":"crossref","first-page":"e213557","DOI":"10.1212\/WNL.0000000000213557","article-title":"Clinical features and factors associated with outcome in late adult-onset myelin oligodendrocyte glycoprotein antibody\u2013associated disease","volume":"104","author":"Dinoto","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.01.269_bib0975","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1136\/jnnp-2023-333133","article-title":"Prognostic factors of first-onset optic neuritis based on diagnostic criteria and antibody status: a multicentre analysis of 427 eyes","volume":"95","author":"Min","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2026.01.269_bib0980","doi-asserted-by":"crossref","first-page":"104237","DOI":"10.1016\/j.msard.2022.104237","article-title":"Details and outcomes of a large cohort of MOG-IgG associated optic neuritis","volume":"68","author":"Chen","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurol.2026.01.269_bib0985","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ajo.2023.02.013","article-title":"Visual outcomes following plasma exchange for optic neuritis: an international multicenter retrospective analysis of 395 optic neuritis attacks","volume":"252","author":"Chen","year":"2023","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.neurol.2026.01.269_bib0990","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/jnnp-2024-334863","article-title":"Apheresis therapies in MOGAD: a retrospective study of 117 therapeutic interventions in 571 attacks","volume":"96","author":"Schwake","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2026.01.269_bib0995","doi-asserted-by":"crossref","first-page":"e213903","DOI":"10.1212\/WNL.0000000000213903","article-title":"Outcomes after acute plasma exchange for myelin oligodendrocyte glycoprotein antibody\u2013associated disease","volume":"105","author":"Thakolwiboon","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.01.269_bib1000","first-page":"426","article-title":"Evolution of brain MRI lesions in paediatric myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and its relevance to disease course","volume":"95","author":"Abdel-mannan","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2026.01.269_bib1005","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ophtha.2024.08.018","article-title":"Radiologic predictors of visual outcome in myelin oligodendrocyte glycoprotein-related optic neuritis","volume":"132","author":"Handzic","year":"2025","journal-title":"Ophthalmology"},{"key":"10.1016\/j.neurol.2026.01.269_bib1010","doi-asserted-by":"crossref","first-page":"e1912732","DOI":"10.1001\/jamanetworkopen.2019.12732","article-title":"Comparison of clinical outcomes of transverse myelitis among adults with myelin oligodendrocyte glycoprotein antibody vs aquaporin-4 antibody disease","volume":"2","author":"Mariano","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.neurol.2026.01.269_bib1015","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/jnnp-2022-330237","article-title":"Prognostic relevance of quantitative and longitudinal MOG antibody testing in patients with MOGAD: a multicentre retrospective study","volume":"94","author":"Gastaldi","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2026.01.269_bib1020","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s00415-018-9160-9","article-title":"Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults","volume":"266","author":"Cobo-Calvo","year":"2019","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2026.01.269_bib1025","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejpn.2024.05.011","article-title":"Frequency and clinical relevance of MOG-antibodies in CSF in pediatric patients with MOG antibody-associated diseases","volume":"51","author":"Galati","year":"2024","journal-title":"Eur J Paediatr Neurol EJPN"},{"key":"10.1016\/j.neurol.2026.01.269_bib1030","first-page":"e1095","article-title":"Significance of myelin oligodendrocyte glycoprotein antibodies in CSF: a retrospective multicenter study","volume":"100","author":"Carta\u00c1lvaro Cobo Calvo","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.01.269_bib1035","doi-asserted-by":"crossref","first-page":"e1095","DOI":"10.1212\/NXI.0000000000001095","article-title":"Myelin oligodendrocyte glycoprotein-immunoglobulin G in the CSF: clinical implication of testing and association with disability","volume":"9","author":"Kwon","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinfl"},{"key":"10.1016\/j.neurol.2026.01.269_bib1040","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1177\/13524585241254731","article-title":"Contributions of CSF interleukin-6 elevation to the pathogenesis of myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"30","author":"Uzawa","year":"2024","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"key":"10.1016\/j.neurol.2026.01.269_bib1045","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1136\/jnnp-2018-317969","article-title":"CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications","volume":"89","author":"Kaneko","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2026.01.269_bib1050","doi-asserted-by":"crossref","first-page":"e200362","DOI":"10.1212\/NXI.0000000000200362","article-title":"Profile and usefulness of serum cytokines to predict prognosis in myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"12","author":"Villacieros-\u00c1lvarez","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.neurol.2026.01.269_bib1055","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurol.2026.01.269_bib1060","doi-asserted-by":"crossref","first-page":"647618","DOI":"10.3389\/fimmu.2021.647618","article-title":"Serum neurofilament light and gfap are associated with disease severity in inflammatory disorders with aquaporin-4 or myelin oligodendrocyte glycoprotein antibodies","volume":"12","author":"Chang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurol.2026.01.269_bib1065","article-title":"Serum neurofilament light chain in NMOSD and related disorders: comparison according to aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies status","volume":"3","author":"Mariotto","year":"2017","journal-title":"Mult Scler J - Exp Transl Clin"},{"key":"10.1016\/j.neurol.2026.01.269_bib1070","doi-asserted-by":"crossref","first-page":"e200347","DOI":"10.1212\/NXI.0000000000200347","article-title":"Neurofilament light chain as a discriminator of disease activity status in MOG antibody-associated disease","volume":"12","author":"Gomes ABAGR","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.neurol.2026.01.269_bib1075","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1136\/jnnp-2024-335137","article-title":"Assessment of neuronal and glial serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease: the MULTIMOGAD study","volume":"96","author":"Marignier","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2026.01.269_bib1080","doi-asserted-by":"crossref","first-page":"102833","DOI":"10.1016\/j.msard.2021.102833","article-title":"NfL levels predominantly increase at disease onset in MOG-Abs-associated disorders","volume":"50","author":"Mariotto","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurol.2026.01.269_bib1085","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1177\/13524585211063756","article-title":"Absence of attack-independent neuroaxonal injury in MOG antibody-associated disease: longitudinal assessment of serum neurofilament light chain","volume":"28","author":"Hyun","year":"2022","journal-title":"Mult Scler J"},{"key":"10.1016\/j.neurol.2026.01.269_bib1090","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1136\/jnnp-2018-320287","article-title":"Neurofilament light chain serum levels reflect disease severity in MOG-Ab associated disorders","volume":"90","author":"Mariotto","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2026.01.269_bib1095","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jneuroim.2021.577699","article-title":"C3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD","volume":"360","author":"Pache","year":"2021","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.neurol.2026.01.269_bib1100","doi-asserted-by":"crossref","first-page":"853891","DOI":"10.3389\/fimmu.2022.853891","article-title":"Plasma complement 3 and complement 4 are promising biomarkers for distinguishing NMOSD from MOGAD and are associated with the blood-brain-barrier disruption in NMOSD","volume":"13","author":"Lin","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurol.2026.01.269_bib1105","doi-asserted-by":"crossref","first-page":"1320094","DOI":"10.3389\/fimmu.2024.1320094","article-title":"Differentiated pattern of complement system activation between MOG-IgG-associated disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder","volume":"15","author":"Cho","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurol.2026.01.269_bib1110","doi-asserted-by":"crossref","first-page":"e200340","DOI":"10.1212\/NXI.0000000000200340","article-title":"Complement activation profiles predict clinical outcomes in myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"12","author":"Villacieros-\u00c1lvarez","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.neurol.2026.01.269_bib1115","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12974-019-1525-1","article-title":"Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease","volume":"16","author":"Cobo-Calvo","year":"2019","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.neurol.2026.01.269_bib1120","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1007\/s00415-021-10914-x","article-title":"Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"269","author":"Akaishi","year":"2022","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2026.01.269_bib1125","doi-asserted-by":"crossref","first-page":"e2142780","DOI":"10.1001\/jamanetworkopen.2021.42780","article-title":"Factors associated with relapse and treatment of myelin oligodendrocyte glycoprotein antibody\u2013associated disease in the United Kingdom","volume":"5","author":"Satukijchai","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.neurol.2026.01.269_bib1130","doi-asserted-by":"crossref","first-page":"106631","DOI":"10.1016\/j.msard.2025.106631","article-title":"Relapse and disability outcomes in incident MOGAD patients undergoing watchful waiting after onset","volume":"102","author":"Tisavipat","year":"2025","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurol.2026.01.269_bib1135","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/jamaneurol.2019.2940","article-title":"Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes","volume":"77","author":"Waters","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2026.01.269_bib1140","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/ana.26731","article-title":"Do early relapses predict the risk of long-term relapsing disease in an adult and paediatric cohort with MOGAD?","volume":"94","author":"Chen","year":"2023","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2026.01.269_bib1145","doi-asserted-by":"crossref","first-page":"e055392","DOI":"10.1136\/bmjopen-2021-055392","article-title":"Predictors of relapse in MOG antibody associated disease: a cohort study","volume":"11","author":"Huda","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.neurol.2026.01.269_bib1150","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","article-title":"Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"75","author":"Hacohen","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2026.01.269_bib1155","doi-asserted-by":"crossref","first-page":"e200065","DOI":"10.1212\/NXI.0000000000200065","article-title":"Early immunotherapy and longer corticosteroid treatment are associated with lower risk of relapsing disease course in pediatric MOGAD","volume":"10","author":"Nosadini","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.neurol.2026.01.269_bib1160","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jamaneurol.2024.2811","article-title":"Time to treat first acute attack of myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"81","author":"Kwon","year":"2024","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2026.01.269_bib1165","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1136\/jnnp-2024-333463","article-title":"Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse","volume":"95","author":"Trewin","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2026.01.269_bib1170","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1212\/WNL.0000000000009758","article-title":"Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder","volume":"95","author":"Chen","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.01.269_bib1175","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/jnnp-2024-333464","article-title":"Predictors of a relapsing course in myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"96","author":"Virupakshaiah","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2026.01.269_bib1180","doi-asserted-by":"crossref","first-page":"e705","DOI":"10.1212\/NXI.0000000000000705","article-title":"Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders","volume":"7","author":"Li","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.neurol.2026.01.269_bib1185","doi-asserted-by":"crossref","first-page":"102251","DOI":"10.1016\/j.msard.2020.102251","article-title":"Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients","volume":"44","author":"Whittam","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurol.2026.01.269_bib1190","doi-asserted-by":"crossref","first-page":"e2504","DOI":"10.1212\/WNL.0000000000201260","article-title":"Long-term effectiveness and safety of rituximab in neuromyelitis optica spectrum disorder and MOG antibody disease","volume":"99","author":"Barreras","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.01.269_bib1195","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/jnnp-2022-330086","article-title":"Efficacy and safety of rituximab in myelin oligodendrocyte glycoprotein antibody-associated disorders compared with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis","volume":"94","author":"Spagni","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2026.01.269_bib1200","doi-asserted-by":"crossref","first-page":"577812","DOI":"10.1016\/j.jneuroim.2022.577812","article-title":"Safety and efficacy of rituximab for relapse prevention in myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG)-associated disorders (MOGAD): a systematic review and meta-analysis","volume":"364","author":"Nepal","year":"2022","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.neurol.2026.01.269_bib1205","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/ana.25648","article-title":"Comparison of the response to rituximab between myelin oligodendrocyte glycoprotein and aquaporin-4 antibody diseases","volume":"87","author":"Durozard","year":"2020","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2026.01.269_bib1210","doi-asserted-by":"crossref","first-page":"e1100","DOI":"10.1212\/NXI.0000000000001100","article-title":"Interleukin-6 receptor blockade in treatment-refractory MOG-IgG-associated disease and neuromyelitis optica spectrum disorders","volume":"9","author":"Ringelstein","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.neurol.2026.01.269_bib1215","doi-asserted-by":"crossref","first-page":"e200243","DOI":"10.1212\/NXI.0000000000200243","article-title":"Life-threatening MOG antibody-associated hemorrhagic ADEM with elevated CSF IL-6","volume":"11","author":"Virupakshaiah","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.neurol.2026.01.269_bib1220","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/13524585241226830","article-title":"Effectiveness of immunotherapies in relapsing myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"30","author":"Bilodeau","year":"2024","journal-title":"Mult Scler J"},{"key":"10.1016\/j.neurol.2026.01.269_bib1225","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/jamaneurol.2022.0489","article-title":"Association of maintenance intravenous immunoglobulin with prevention of relapse in adult myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"79","author":"Chen","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2026.01.269_bib1230","doi-asserted-by":"crossref","first-page":"e200309","DOI":"10.1212\/NXI.0000000000200309","article-title":"A simple score (MOG-AR) to identify individuals at high risk of relapse after MOGAD attack","volume":"11","author":"Xu","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.neurol.2026.01.269_bib1235","doi-asserted-by":"crossref","first-page":"e2137833","DOI":"10.1001\/jamanetworkopen.2021.37833","article-title":"Frequency of new silent MRI lesions in myelin oligodendrocyte glycoprotein antibody disease and aquaporin-4 antibody neuromyelitis optica spectrum disorder","volume":"4","author":"Camera","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.neurol.2026.01.269_bib1240","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1212\/WNL.0000000000201263","article-title":"Frequency of new or enlarging lesions on MRI outside of clinical attacks in patients with MOG-antibody-associated disease","volume":"99","author":"Syc-Mazurek","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.01.269_bib1245","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ana.25957","article-title":"Silent new brain MRI Lesions in children with MOG-antibody associated disease","volume":"89","author":"Fadda","year":"2021","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2026.01.269_bib1250","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.neurad.2022.11.003","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease in children: are there MRI predictors of relapse?","volume":"50","author":"Singh","year":"2023","journal-title":"J Neuroradiol J Neuroradiol"},{"key":"10.1016\/j.neurol.2026.01.269_bib1255","doi-asserted-by":"crossref","first-page":"867190","DOI":"10.3389\/fneur.2022.867190","article-title":"Volumetric brain loss correlates with a relapsing MOGAD disease course","volume":"13","author":"Rechtman","year":"2022","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurol.2026.01.269_bib1260","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/13524585211018987","article-title":"Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis","volume":"28","author":"Messina","year":"2022","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"key":"10.1016\/j.neurol.2026.01.269_bib1265","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/brain\/awaa347","article-title":"Quantitative spinal cord MRI in MOG-antibody disease, neuromyelitis optica and multiple sclerosis","volume":"144","author":"Mariano","year":"2021","journal-title":"Brain J Neurol"},{"key":"10.1016\/j.neurol.2026.01.269_bib1270","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s40478-019-0786-3","article-title":"Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination","volume":"7","author":"Tea","year":"2019","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.neurol.2026.01.269_bib1275","doi-asserted-by":"crossref","first-page":"e200035","DOI":"10.1212\/NXI.0000000000200035","article-title":"Temporal dynamics of MOG antibodies in children with acquired demyelinating syndrome","volume":"9","author":"Wendel","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.neurol.2026.01.269_bib1280","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s12974-020-01824-2","article-title":"Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients","volume":"17","author":"Jarius","year":"2020","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.neurol.2026.01.269_bib1285","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12974-020-01825-1","article-title":"Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: results from 108 lumbar punctures in 80 pediatric patients","volume":"17","author":"Jarius","year":"2020","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.neurol.2026.01.269_bib1290","doi-asserted-by":"crossref","first-page":"102638","DOI":"10.1016\/j.msard.2020.102638","article-title":"Variability of cerebrospinal fluid findings by attack phenotype in myelin oligodendrocyte glycoprotein-IgG-associated disorder","volume":"47","author":"Sechi","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurol.2026.01.269_bib1295","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1177\/13524585241311435","article-title":"Evaluation of the predictive value of CSF-restricted oligoclonal bands on residual disability and risk of relapse in adult patients with MOGAD: MOGADOC study","volume":"31","author":"Ramdani","year":"2025","journal-title":"Mult Scler J"},{"key":"10.1016\/j.neurol.2026.01.269_bib1300","doi-asserted-by":"crossref","first-page":"105935","DOI":"10.1016\/j.msard.2024.105935","article-title":"Blood neutrophils, oligoclonal bands and bridging corticosteroids as predictive factors for MOGAD course: insights from a multicentric Portuguese cohort","volume":"92","author":"Neves","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurol.2026.01.269_bib1305","doi-asserted-by":"crossref","first-page":"1211776","DOI":"10.3389\/fimmu.2023.1211776","article-title":"Comparing clinical and imaging features of patients with MOG antibody-positivity and with and without oligoclonal bands","volume":"14","author":"Tomizawa","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurol.2026.01.269_bib1310","doi-asserted-by":"crossref","first-page":"105034","DOI":"10.1016\/j.msard.2023.105034","article-title":"Dual positivity for anti-MOG and oligoclonal bands: Unveiling unique clinical profiles and implications","volume":"79","author":"Ganelin-Cohen","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurol.2026.01.269_bib1315","first-page":"290","article-title":"MOG antibody non-P42 epitope is associated with a higher risk of relapse in paediatric MOGAD","volume":"31","author":"El Hajj","year":"2025","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2026.01.269_bib1320","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1136\/jnnp-2023-332851","article-title":"The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-associated disease","volume":"95","author":"Liyanage","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2026.01.269_bib1325","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.intimp.2016.04.006","article-title":"Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were associated with disease activity in patients with systemic lupus erythematosus","volume":"36","author":"Wu","year":"2016","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.neurol.2026.01.269_bib1330","doi-asserted-by":"crossref","first-page":"104796","DOI":"10.1016\/j.msard.2023.104796","article-title":"Novel index, neutrophil percentage (%) is a useful marker for disease activity in MOG antibody-associated disease","volume":"76","author":"Baek","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurol.2026.01.269_bib1335","doi-asserted-by":"crossref","first-page":"102345","DOI":"10.1016\/j.msard.2020.102345","article-title":"Neutrophil-to-lymphocyte ratio correlates with disease activity in myelin oligodendrocyte glycoprotein antibody associated disease (MOGAD) in children","volume":"45","author":"Benetou","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurol.2026.01.269_bib1340","doi-asserted-by":"crossref","first-page":"6481","DOI":"10.1038\/s41598-023-33827-3","article-title":"White blood cell count profiles in anti-aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorder and anti-myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"13","author":"Akaishi","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurol.2026.01.269_bib1345","doi-asserted-by":"crossref","first-page":"104570","DOI":"10.1016\/j.msard.2023.104570","article-title":"Neutrophil to lymphocyte ratio may be a useful marker in distinguishing MOGAD and MS and platelet to lymphocyte ratio associated with MOGAD activity","volume":"71","author":"Lin","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurol.2026.01.269_bib1350","doi-asserted-by":"crossref","first-page":"577467","DOI":"10.1016\/j.jneuroim.2020.577467","article-title":"Progression pattern of neurological disability with respect to clinical attacks in anti-MOG antibody-associated disorders","volume":"351","author":"Akaishi","year":"2021","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.neurol.2026.01.269_bib1355","doi-asserted-by":"crossref","first-page":"105093","DOI":"10.1016\/j.msard.2023.105093","article-title":"Progression independent of relapses in aquaporin4-IgG-seropositive neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, and multiple sclerosis","volume":"80","author":"Molazadeh","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurol.2026.01.269_bib1360","doi-asserted-by":"crossref","first-page":"e1376","DOI":"10.1212\/WNL.0000000000207478","article-title":"Timing and predictors of T2-lesion resolution in patients with myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"101","author":"Cacciaguerra","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.01.269_bib1365","doi-asserted-by":"crossref","first-page":"e1097","DOI":"10.1212\/WNL.0000000000012467","article-title":"Comparison of MRI lesion evolution in different central nervous system demyelinating disorders","volume":"97","author":"Sechi","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.01.269_bib1370","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1177\/13524585231166834","article-title":"Comparison of MRI T2-lesion evolution in pediatric MOGAD, NMOSD, and MS","volume":"29","author":"Redenbaugh","year":"2023","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"key":"10.1016\/j.neurol.2026.01.269_bib1375","doi-asserted-by":"crossref","first-page":"e200277","DOI":"10.1212\/NXI.0000000000200277","article-title":"Frequency of asymptomatic optic nerve enhancement in 203 patients with MOG antibody-associated disease","volume":"11","author":"Tajfirouz","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.neurol.2026.01.269_bib1380","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1177\/1352458520964415","article-title":"Brain structural and functional alterations in MOG antibody disease","volume":"27","author":"Zhuo","year":"2021","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"key":"10.1016\/j.neurol.2026.01.269_bib1385","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1002\/acn3.52137","article-title":"Cortical atrophy patterns in myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"11","author":"Schneider","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurol.2026.01.269_bib1390","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/ana.26951","article-title":"Grey matter atrophy and its relationship with white matter lesions in patients with myelin oligodendrocyte glycoprotein antibody-associated disease, aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder, and multiple sclerosis","volume":"96","author":"Cortese","year":"2024","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2026.01.269_bib1395","doi-asserted-by":"crossref","first-page":"e425","DOI":"10.1212\/WNL.0000000000207429","article-title":"Deviation from normative whole brain and deep gray matter growth in children with MOGAD, MS, and monophasic seronegative demyelination","volume":"101","author":"Fadda","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.01.269_bib1400","doi-asserted-by":"crossref","first-page":"e200325","DOI":"10.1212\/NXI.0000000000200325","article-title":"Cognitive impairment, associated clinical factors, and MR volumetric measures in myelin oligodendrocyte glycoprotein-IgG\u2013associated disease","volume":"11","author":"Kogel","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.neurol.2026.01.269_bib1405","doi-asserted-by":"crossref","first-page":"104436","DOI":"10.1016\/j.msard.2022.104436","article-title":"Volumetric brain changes in MOGAD: a cross-sectional and longitudinal comparative analysis","volume":"69","author":"Lotan","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurol.2026.01.269_bib1410","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/jon.13175","article-title":"A longitudinal analysis of brain volume changes in myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"34","author":"Amin","year":"2024","journal-title":"J Neuroimaging"},{"key":"10.1016\/j.neurol.2026.01.269_bib1415","doi-asserted-by":"crossref","first-page":"e209156","DOI":"10.1212\/WNL.0000000000209156","article-title":"Trans-synaptic degeneration in the visual pathway in patients with myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"102","author":"Bollo","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.01.269_bib1420","doi-asserted-by":"crossref","first-page":"103001","DOI":"10.1016\/j.nicl.2022.103001","article-title":"Patterns of white and gray structural abnormality associated with paediatric demyelinating disorders","volume":"34","author":"Bells","year":"2022","journal-title":"NeuroImage Clin"},{"key":"10.1016\/j.neurol.2026.01.269_bib1425","doi-asserted-by":"crossref","first-page":"673472","DOI":"10.3389\/fneur.2021.673472","article-title":"Structural and functional alterations in visual pathway after optic neuritis in MOG antibody disease: a comparative study with AQP4 seropositive NMOSD","volume":"12","author":"Gao","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurol.2026.01.269_bib1430","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1212\/WNL.0000000000201465","article-title":"Differentiating multiple sclerosis from AQP4-neuromyelitis optica spectrum disorder and MOG-antibody disease with imaging","volume":"100","author":"Cortese","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.01.269_bib1435","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1136\/jnnp-2020-324826","article-title":"Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS","volume":"92","author":"Duan","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2026.01.269_bib1440","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3174\/ajnr.A8066","article-title":"Glymphatic system dysfunction in myelin oligodendrocyte glycoprotein immunoglobulin G antibody\u2013associated disorders: association with clinical disability","volume":"45","author":"Hagiwara","year":"2023","journal-title":"Am J Neuroradiol"},{"key":"10.1016\/j.neurol.2026.01.269_bib1445","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1177\/1352458518815596","article-title":"Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity","volume":"25","author":"Chien","year":"2019","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"key":"10.1016\/j.neurol.2026.01.269_bib1450","doi-asserted-by":"crossref","first-page":"103525","DOI":"10.1016\/j.msard.2022.103525","article-title":"OCT Retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG antibody-associated disease and multiple sclerosis","volume":"58","author":"Chen","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurol.2026.01.269_bib1455","doi-asserted-by":"crossref","first-page":"540156","DOI":"10.3389\/fneur.2020.540156","article-title":"AQP4-IgG and MOG-IgG related optic neuritis-prevalence, optical coherence tomography findings, and visual outcomes: a systematic review and meta-analysis","volume":"11","author":"Filippatou","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurol.2026.01.269_bib1460","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1177\/1352458519864928","article-title":"Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning","volume":"26","author":"Sotirchos","year":"2020","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"key":"10.1016\/j.neurol.2026.01.269_bib1465","doi-asserted-by":"crossref","first-page":"6366","DOI":"10.1007\/s00415-022-11256-y","article-title":"Characteristic retinal atrophy pattern allows differentiation between pediatric MOGAD and MS after a single optic neuritis episode","volume":"269","author":"Pakeerathan","year":"2022","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2026.01.269_bib1470","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00415-016-8333-7","article-title":"Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration","volume":"264","author":"Havla","year":"2017","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2026.01.269_bib1475","doi-asserted-by":"crossref","first-page":"1029124","DOI":"10.3389\/fimmu.2023.1029124","article-title":"Retinal structural and microvascular changes in myelin oligodendrocyte glycoprotein antibody disease and neuromyelitis optica spectrum disorder: An OCT\/OCTA study","volume":"14","author":"Lang","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurol.2026.01.269_bib1480","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/ana.26440","article-title":"Longitudinal retinal changes in MOGAD","volume":"92","author":"Oertel","year":"2022","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2026.01.269_bib1485","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12974-016-0720-6","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients","volume":"13","author":"Pache","year":"2016","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.neurol.2026.01.269_bib1490","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1093\/brain\/awac317","article-title":"The use of optical coherence tomography in neurology: a review","volume":"145","author":"Xie","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2026.01.269_bib1495","doi-asserted-by":"crossref","first-page":"e0130175","DOI":"10.1371\/journal.pone.0130175","article-title":"Microcystic inner nuclear layer changes and retinal nerve fiber layer defects in eyes with glaucoma","volume":"10","author":"Hasegawa","year":"2015","journal-title":"PLOS One"},{"key":"10.1016\/j.neurol.2026.01.269_bib1500","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1167\/iovs.13-12912","article-title":"The clinical spectrum of microcystic macular edema","volume":"55","author":"Burggraaff","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.neurol.2026.01.269_bib1505","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1212\/WNL.0b013e31828c2f7a","article-title":"In vivo identification of morphologic retinal abnormalities in neuromyelitis optica","volume":"80","author":"Sotirchos","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.01.269_bib1510","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.1097\/WNO.0000000000001116","article-title":"Alterations in the retinal vascular network and structure in MOG antibody-associated disease: an optical coherence tomography angiography study","volume":"41","author":"Yu","year":"2021","journal-title":"J Neuro-Ophthalmol"},{"key":"10.1016\/j.neurol.2026.01.269_bib1515","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/s12883-022-02848-2","article-title":"The difference of the retinal structural and microvascular characteristics in patients with MOGAD-ON and AQP4-ON","volume":"22","author":"Yao","year":"2022","journal-title":"BMC Neurol"},{"key":"10.1016\/j.neurol.2026.01.269_bib1520","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.msard.2018.11.026","article-title":"Unique characteristics of optical coherence tomography (OCT) results and visual acuity testing in myelin oligodendrocyte glycoprotein (MOG) antibody positive pediatric patients","volume":"28","author":"Narayan","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurol.2026.01.269_bib1525","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ejpn.2023.12.006","article-title":"Visual outcome measures in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)","volume":"48","author":"Gericke","year":"2023","journal-title":"Eur J Paediatr Neurol EJPN"},{"key":"10.1016\/j.neurol.2026.01.269_bib1530","doi-asserted-by":"crossref","first-page":"fcad063","DOI":"10.1093\/braincomms\/fcad063","article-title":"Early blood neurofilament light chain and myelin oligodendrocyte glycoprotein antibody levels associate with different disease courses of myelin oligodendrocyte glycoprotein-associated disease in children","volume":"5","author":"Horellou","year":"2023","journal-title":"Brain Commun"},{"key":"10.1016\/j.neurol.2026.01.269_bib1535","doi-asserted-by":"crossref","first-page":"105729","DOI":"10.1016\/j.msard.2024.105729","article-title":"Longitudinal change of serum NfL as disease activity biomarker candidate in MOGAD: a descriptive cohort study","volume":"88","author":"Schindler","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurol.2026.01.269_bib1540","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1136\/jnnp-2015-312676","article-title":"Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies","volume":"87","author":"Kaneko","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378726004534?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378726004534?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T08:49:40Z","timestamp":1776156580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378726004534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":154,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0035378726004534"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2026.01.269","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognosis biomarkers in MOGAD: What can we learn from observational studies?","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2026.01.269","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}